Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Executive Summary
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
You may also be interested in...
Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Merck & Co Takes Up Astex/Taiho SHP2 Program
Merck & Co joins ranks of big pharma firms pursuing the SHP2 area of oncology as it picks up global rights to a portfolio of inhibitors originating from two affiliates of Japan's Otsuka Pharmaceutical.